The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
View Top Employees from RS BioTherapeutics, Inc.Website | https://www.rsbiotherapeutics.com |
Employees | 7 (5 on RocketReach) |
Industry | Pharmaceutical Manufacturing |
Looking for a particular RS BioTherapeutics, Inc. employee's phone or email?
Michelle Shuffett is the Chief Medical Officer of RS BioTherapeutics, Inc..
5 people are employed at RS BioTherapeutics, Inc..
RS BioTherapeutics, Inc. is based in Cumberland, Maryland.